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(friction cost method) were considered at 1998 price
levels. Future costs were always discounted at 4% while
future effects (QALYs and LYG) were only discounted 
for computing cost-effectiveness ratios. The study time
horizon was 77 years. RESULTS: The vaccination
program would prevent 228 deaths, 92 severe sequelae
(amputations and neurological sequelae) and render
11,330 life years and 13,470 QALYs (no discounting). 
It would cost €75.6 million and avert €27.5 million 
direct costs and €0.4 million indirect costs. The cost-
effectiveness ratio is €11,830/QALY or €14,070/LYG,
when indirect costs are excluded. Considering indirect
costs leads to slightly better ratios: €11,730/QALY or
€13,950/LYG. These results are sensitive to the incidence
of meningococcal C infections, the discount rate of health
effects and the vaccine’s protection duration. CONCLU-
SIONS: The vaccination program renders a signiﬁcant
health gain and is cost-effective as its cost-effectiveness
ratios lie signiﬁcantly below the Dutch cut-off point for
vaccines. These results played an important role in the
Dutch government’s decision to implement this vaccina-
tion program in June 2002.
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OBJECTIVE: Antibiotic resistance is a major public
health problem. In the UK prescribing data are currently
routinely available at the level of a primary care practice.
There are both ﬁnancial and data protection barriers to
analysis of data about individuals. The aim of this study
was to test the null hypothesis that, in comparison with
practice level data, there is no added value to patient level
data for measurement of the association between anti-
biotic prescribing and resistance. METHODS: We per-
formed a cross sectional study that linked data about
resistance to trimethoprim in bacteria isolated from urine
samples to prescribing of trimethoprim and other antibi-
otics. We used a random coefﬁcient model with random
and ﬁxed effects, effectively a multi-level model with two
levels: primary care practice and individual patient.
RESULTS: The study included 31 practices with a total
study population of approximately 179,000 people. The
population of a single practice ranged from 1386 to
10,479. There was considerable variation between prac-
tices in both the prevalence of trimethoprim resistance
(from 15% to 50% of bacteria isolated) and trimetho-
prim prescribing (from 71 prescriptions to 312 prescrip-
tions per 100 people in the practice). Nonetheless, in a
multivariate analysis there was no relationship between
variation in prescribing and resistance (p = 0.2717). In
contrast, at the patient level there was a highly signiﬁcant
relationship between trimethoprim resistance and prior
exposure to trimethoprim (p < 0.0001) and antibiotics
other than trimethoprim (p = 0.0128). CONCLUSIONS:
Analysis of practice level data obscures important rela-
tionships between antibiotic prescribing and resistance.
This is an example of the ecological fallacy, which
assumes that differences in exposure at the population
level indicate similar differences in exposure to the indi-
viduals within the population. Our results are an impor-
tant demonstration of the added value of individual
patient data for research on the outcomes of prescribing.
MIGRAINE/COPD STUDIES
MC1
DEVELOPMENT OF A FUNCTIONAL
ASSESSMENT IN MIGRAINEURS MEASUREMENT
TOOL BASED ON THE WHO’S ICIDH2
CLASSIFICATION
Pathak D1, Chisolm D1, Funk-Orsini P2, Mackell J2,Weis KA2
1The Ohio State University, Columbus, OH, USA; 2Pﬁzer, Inc,
New York, NY, USA
OBJECTIVES: As new medications for migraine are
introduced, it is imperative that valid tools exist to
measure their impact on patient reported outcomes. The
objective of this project was to develop a Migraine Impact
on Functioning (MIF) Tool based on the “body and mind
functioning (BMF)” and “activity and participation (AP)”
framework presented in the ICIDH2. METHODS: The
tool was developed using a multi-step process ﬁrst pro-
posed by Guyatt. 1) Researchers generated an extensive
list of potential items based on focus groups in Germany
and the US and on review of literature. An item reduc-
tion survey was designed including 71 BMF items and 50
AP items. 2) The item reduction survey assessing the fre-
quency and importance of each item was administered to
samples of migraineurs in Germany (n = 153) and the US
(n = 148). 3) Item reduction was completed by selecting
items with high frequency-weighted importance and by
further analyzing these items using Principal Component
analysis. Differences between items selected in the two
populations were compared to determine if one tool could
meet the needs of both. RESULTS: While results from the
German and US populations identiﬁed BMF items as
important, principal components analysis found similar-
ity in the nature of the factors identiﬁed. In the US, a four-
factor, 13-item model was identiﬁed, including: “energy”,
“intolerance to stimulus”, “emotional impact”, and
“attention/psychomotor issues”. In Germany, a 3-factor,
12-item model was found including “attention/cogni-
tion”, “intolerance to stimulus”, and “emotional issues”.
CONCLUSION: Given the notable overlap in the factors
identiﬁed in the two nations, we believe that the differ-
ence in individual item selection is a product of small
translational or interpretational difference rather than an
